Bryxta 400 Injection Bryxta 400 is a bevacizumab-based targeted cancer medicine supplied for intravenous infusion. Bevacizumab works by blocking VEGF-A, a growth signal that helps tumors develop new blood vessels. By interfering with this process, the medicine can reduce the blood supply supporting tumor growth. It is used as part of treatment regimens for several cancers and must be administered by a qualified healthcare professional.